Novel small molecule activator promotes cardiac protection and repair

Potent, selective, small molecule activator of steroid receptor co-activators (SRC) as potential therapeutics for preservation, healing, and restoration of cardiac tissue after a heart attack

INDICATIONS: Heart failure

COMPETITIVE ADVANTAGES

Our proprietary MCB-613 compound is simpler to manufacture and shown improved outcomes post heart attack in mouse models

- Low toxicity in mouse cells and whole animal
- Compound ideally suited for oral administration
- Encourages tissue regeneration through microvasculature growth

VALUE PROPOSITIONS

Protects and promotes healing in damaged cardiac tissue post heart attack

- Improved heart function in mice after heart attack and treatment with MCB-613
- Increases cardioprotective metabolites
- Increases white blood cell production
- Decreases enlarged heart weight and size
- Stimulates regenerative activities in heart tissue
- Prevents enlarged heart, tissue damage, thickening of the heart muscle, and collagen deposition in heart tissue up to 10 weeks after heart attack

INDUSTRY APPETITE

There is a smaller investment appetite with a bigger payload for pharma companies in heart failure therapies with two major acquisition from 2019 to 2020 totaling to $22 billion.

- SRC offers novel pathway for co-activators like MCB-613
- Heart failure market has value of $4.2 billion
- 10 possible treatment options for prescribers to choose in chronic and acute heart failure with several being small molecule technologies
- Players in the space Novartis, AstraZeneca, Bayer, Servier, Merck, Jardiance
- Current drugs in development in similar but not overlapping pathway regulation
- October 2020: Bristol-Myers Squibb Acquires MyoKardia for $13.1 billion for cardiovascular drug portfolio under Phase III

MARKET ANALYSIS

Current treatment options for heart failure are surgery, vasodilators, water pills, heart transplant, or implantable devices. There is a scarcity of assets in the market and large unmet need.

- $22.1 Billion Market estimates for heart disease market by 2028
- $219 Billion Heart disease cost the US from healthcare services, medicines, and loss of productivity
- 655,000 People die from heart disease in United States per year and is the number one killer